MeiraGTx Holdings PLC (FRA:328)
€ 6.1 -0.2 (-3.17%) Market Cap: 500.99 Mil Enterprise Value: 466.77 Mil PE Ratio: 0 PB Ratio: 5.50 GF Score: 47/100

MeiraGTx Holdings PLC at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript

Nov 16, 2020 / 06:30PM GMT
Release Date Price: €12.4 (-0.80%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Welcome, everyone. My name is Gena Wang. I'm SMID cap biotech analyst at Barclays. It's my great pleasure to introduce our next presenting company MeiraGTx. With me on the Zoom meeting is Zandy Forbes, President and Chief Executive Officer; and also Elizabeth Anderson, VP of Investor Relations.

With that, I hand over to you, Zandy.

Alexandria Forbes
MeiraGTx Holdings plc - CEO, President & Director

Thank you, Gena, and thank you for Barclays inviting us to speak and chat with you at this conference. I'm going to give a quick overview of the company. And then I think we will touch on a number of aspects I'm going to mention in our conversation. So if we could go to the first slide, please, Elizabeth.

So Meira is a gene therapy company that was really formed to address or innovate in this new space of gene therapy to create pharmaceuticals that could cost effectively treat a broad range of serious disorders. That means that from the perspective of Meira, we're really

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot